ACTIVATION OF PROTHROMBIN IN WHOLE HUMAN BLOOD

这项研究最初是为了评估 蛋白酶酶学与血小板活化 诱导最小程度改变的全血凝结。这些技术 现在被用于两个不同但相关的研究。在一项研究中， 出血或凝血异常的患者，包括各种 蛋白质缺乏症，研究。在另一项研究中， 将抑制剂添加到正常个体的血液中， 然后在存在和不存在这种物质的情况下检查凝结过程。 抑制剂的此外，阿司匹林将被给予正常 志愿者检查阿司匹林对血液凝固的影响 通路 测试受试者的纤维蛋白原、凝血酶原时间和活化凝血酶原时间。 部分凝血活酶时间、血细胞图和化学13谱是 得到了受试者在研究阿司匹林的影响进行测试 在服用阿司匹林之前和服用650 mg/天阿司匹林3天之后 天在血小板抑制剂的研究中，抑制剂存在于 一系列的试管，其中加入血液，而对照组中没有 系列.

This study was initially conducted to evaluate the relationship between protease enzymology and platelet activation during the tissue factor induced clotting of minimally altered whole blood. These techniques are now being utilized in two different but related studies. In one study, patients with bleeding or clotting abnormalities, including various protein deficiencies, are studied. In the other study, various platelet inhibitors are added to the blood of normal individuals, and the coagulation process is then examined in the presence and absence of such inhibitors . In addition asprin will be administered to normal volunteers to examine the influence of aspirin in the blood clotting pathway. Subjects are tested for fibrinogen, prothrombin time and activated partial thromboplastin time and hemagrams and chem 13 profiles are obtained. Subjects in the study of the effects of aspirin are tested before aspirin is given and after receiving 650 mg/day aspirin for 3 days. In the study of platelet inhibitors, the inhibitor is present in one series of tubes to which blood is added and is absent in a control series.